Arthneeti
All Q3 FY26 results →
L

Lupin Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Lupin Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,202
Market cap₹1.0L Cr
P/E17.2
Updated23 Aug 2026
Read4 min read

The short version

Future growth expectations for Lupin's sales/revenue/volumes: - India business aims for continued double-digit growth, targeting 20%-30% above market growth, driven by chronic therapies and new initiatives like added salesforce and innovative products (Page 17). Lupin expects to maintain robust top-line growth driven by new products like Mirabegron, Tolvaptan, and biosimilars (Pegfilgrastim, Ranibizumab).

From Lupin Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Future growth expectations for Lupin's sales/revenue/volumes: - India business aims for continued double-digit growth, targeting 20%-30% above market growth, driven by chronic therapies and new initiatives like added salesforce and innovative products (Page 17). - Emerging markets expected to grow strongly, with Brazil doubling sales due to products like Dapagliflozin (Page 19). - US business shows sustained growth, with 46% YoY increase in the recent quarter, driven by new product launches and biosimilars pipeline, including Pegfilgrastim starting FY27 (Pages 5, 9). - EBITDA margins expected at 24%-25% for FY27 with strong top-line buoyancy and cost focus (Page 12). - Specialty and complex products, including Semaglutide and biosimilars, planned for launch over next few years, contributing to growth (Pages 9, 11).

2 more points from Lupin Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Lupin Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Lupin has the ability to borrow about USD 1.5 billion - 1.6 billion apart from existing cash.
  • Capital allocation priorities include acquiring specialty assets in the USD 250 million - 300 million range, possibly more depending on opportunities.
  • Focus on specialty assets in India with a similar sweet spot of about USD 250 million - 300 million.
  • Interested in assets in U.S., Europe, and developed markets like VISUfarma acquisition.
  • Considering clinical-stage assets requiring investment before market launch.

2 more points from Lupin Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lupin Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from the Lupin Limited Q3 FY26 Earnings Call does not explicitly mention the current or expected order book or pending orders. However, key points related to business outlook and growth opportunities include: - Specialty assets acquisitions planned, with a borrowing capacity of USD 1.5 - 1.6 billion and preferred deal sizes around USD 250 - 300 million. - Strong product pipeline with new launches such as Pegfilgrastim biosimilar in the US, and ongoing R&D including Nexplanon® (planned FY28 filing). - Emerging Markets, especially Brazil, showing high growth (Brazil nearly doubled turnover this quarter).

2 more points from Lupin Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Lupin Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹1.5K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Lupin Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lupin Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lupin Ltd Q3 FY26 results?

Future growth expectations for Lupin's sales/revenue/volumes: - India business aims for continued double-digit growth, targeting 20%-30% above market growth, driven by chronic therapies and new initiatives like added salesforce and innovative products (Page 17). Lupin expects to maintain robust top-line growth driven by new products like Mirabegron, Tolvaptan, and biosimilars (Pegfilgrastim, Ranibizumab).

What is Lupin Ltd share price analysis?

Lupin Ltd currently shows a neutral. The stock trades at a P/E of 17.2 with a market cap of ₹102,191 Cr. Investors should review the full earnings analysis for detailed insights.

Is Lupin Ltd planning capital expenditure?

Lupin has the ability to borrow about USD 1.5 billion - 1.6 billion apart from existing cash.

Keep Lupin Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.